So here’s a question. What happens once the 1st drug is shown in RCT to be effective vs COVID? Say, Remdesevir in upcoming Chinese data. So that’s the standard of care. What happens to these seemingly thousands of trials that don’t have a RMD arm? #COVID19 #IDtwitter

Say there’s split decision in Chinese RMD trials. No overall benefit, but benefit in early treatment subgroup. Do I have to inform patients being consented to my non-RMD trial?